Several studies documented an association between thrombosis and ABO blood groups. In particular, non-O blood groups showed a higher risk of myocardial infarction, angina, peripheral vascular disease, cerebral ischemia, and venous thromboembolism (VTE) than O group. We sought to investigate, in a large sample of hospital admissions, the possible association between blood groups and VTE. The study was based on the discharge hospital sheets (DSOs) of patients admitted to the Hospital of Ferrara, region Emilia-Romagna (RER), Italy, 2000 and 2011. We selected all patients with first or second discharge ICD-9-CM diagnosis code of: acute pulmonary heart disease (APHD); pulmonary embolism (PE); phlebitis and thrombophlebitis (PVT); other venous embolism and thrombosis (OVET).Total population was divided into subgroups by gender, age, and presence of risk factors: arterial hypertension, diabetes, overweight-obesity, dyslipidemia, homocystinemia, coagulation defects, gout, and cancer. Moreover, we considered all patients in whom a blood group determination was recorded. There were 345,607 admissions, regarding 164,438 different patients. Of these, 65,402 had their blood group determination. Among these patients, 1,270 had a PE, 828 had a PVT, and 923 had an OVET. In the multivariate analysis, patients with non O blood group, and with A-allele, had a significantly higher risk for VTE (p=0.001) whereas the presence of group O appeared to be protective (p=0.001). This study shows an increased VTE risk in subjects with non O-groups genotypes, ranging from 20% to 35%. In the real world of everyday medical practice, the decision of whether to test for thrombophilia patients with VTE is controversial, due to organizational and economic constraints. Given the social utility of having one’s own blood group determination, and considering the prevalence of non-O blood groups, this could provide general practioners a valid, and relatively inexpensive, first-line tool to evaluate thrombophilic risk.
ABO blood groups and venous thromboembolism in a cohort of 65,402 hospitalized subjects.
MANFREDINI, Roberto
2014
Abstract
Several studies documented an association between thrombosis and ABO blood groups. In particular, non-O blood groups showed a higher risk of myocardial infarction, angina, peripheral vascular disease, cerebral ischemia, and venous thromboembolism (VTE) than O group. We sought to investigate, in a large sample of hospital admissions, the possible association between blood groups and VTE. The study was based on the discharge hospital sheets (DSOs) of patients admitted to the Hospital of Ferrara, region Emilia-Romagna (RER), Italy, 2000 and 2011. We selected all patients with first or second discharge ICD-9-CM diagnosis code of: acute pulmonary heart disease (APHD); pulmonary embolism (PE); phlebitis and thrombophlebitis (PVT); other venous embolism and thrombosis (OVET).Total population was divided into subgroups by gender, age, and presence of risk factors: arterial hypertension, diabetes, overweight-obesity, dyslipidemia, homocystinemia, coagulation defects, gout, and cancer. Moreover, we considered all patients in whom a blood group determination was recorded. There were 345,607 admissions, regarding 164,438 different patients. Of these, 65,402 had their blood group determination. Among these patients, 1,270 had a PE, 828 had a PVT, and 923 had an OVET. In the multivariate analysis, patients with non O blood group, and with A-allele, had a significantly higher risk for VTE (p=0.001) whereas the presence of group O appeared to be protective (p=0.001). This study shows an increased VTE risk in subjects with non O-groups genotypes, ranging from 20% to 35%. In the real world of everyday medical practice, the decision of whether to test for thrombophilia patients with VTE is controversial, due to organizational and economic constraints. Given the social utility of having one’s own blood group determination, and considering the prevalence of non-O blood groups, this could provide general practioners a valid, and relatively inexpensive, first-line tool to evaluate thrombophilic risk.I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
